Letter to the editor: Efficacy of probiotic treatment as postexposure prophylaxis for COVID-19: A double-blind, PlaceboControlled randomized trial

Affiliations

¹ The Second Affiliated College of Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang Province, China.
² Department of Gastroenterology, Tongde Hospital of Zhejiang Province, Street Gucui No.234, Region Xihu, Hangzhou 310012, Zhejiang Province, China. Electronic address: chenmingxian2005@126.com.

Randomized Controlled Trial

Yuan Ji et al. Clin Nutr. 2024 Jun.

. 2024 Jun;43(6):1501-1502.

doi: 10.1016/j.clnu.2024.05.006. Epub 2024 May 6.

¹ The Second Affiliated College of Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang Province, China.
² Department of Gastroenterology, Tongde Hospital of Zhejiang Province, Street Gucui No.234, Region Xihu, Hangzhou 310012, Zhejiang Province, China. Electronic address: chenmingxian2005@126.com.

No abstract available

Keywords: Autoimmunity; COVID-19; Diet and exercise; Hierarchical treatment; Probiotic.

Conflict of interest statement

Conflicts of interest The authors have no conflicts of interest to report.

Efficacy of probiotic treatment as post-exposure prophylaxis for COVID-19: A double-blind, Placebo-Controlled Randomized trial.
Wischmeyer PE, Tang H, Ren Y, Bohannon L, Jiang D, Bergens M, Ramirez ZE, Andermann TM, Messina JA, Sung JA, Jensen D, Jung SH, Artica A, Britt A, Bush A, Johnson E, Lew MV, Winthrop H, Pamanes C, Racioppi A, Zhao AT, Wan Z, Surana NK, Sung AD. Wischmeyer PE, et al. Clin Nutr. 2024 Jan;43(1):259-267. doi: 10.1016/j.clnu.2023.11.043. Epub 2023 Dec 11. Clin Nutr. 2024. PMID: 38103462 Clinical Trial.